|
 |
 |
European BioPharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.
With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.
|
|
 |
|
|
 |
 |
Industry Events |
 |
PAT and Quality by Design for Biopharmaceuticals
25-26 May 2010, London, UK
Pharma IQ is delighted to announce the inaugural PAT and quality by design for biopharmaceuticals, being held in London on the 25th-26th May 2010. With PAT and quality by design techniques now established within the small molecules field the focus is shifting to application within the biopharmaceuticals arena, with key regulatory bodies such as the FDA and EMEA actively getting involved I pilot case studies. This event will bring together professionals specifically tasked with implementing PAT and QbD tools and techniques specifically within the bioprocess and bioproduction area.
More info >> |
|
 |
News and Press Releases |
 |
Successful PA Consulting and ERBI Cambridge seminar for emerging companies points the way to economic recovery
A seminar and dinner held on 26 January at Clare College Cambridge for emerging companies and their investors focusing on Adapting to life in the new economic environment – the challenge for start-ups attracted full attendance, demonstrating that venture-backed companies may be ahead in planning for the future and leading the UK out of recession.
More info >> |
|
|